First Tracks Biotherapeutics is trading at $32.25, down 5.29%, with no clear company-specific cause identified and the biotech sector also lower. - It closed at $34.05 on October 12; XBI fell 2.01% during the regular session on October 13. - Positive Phase 1b celiac-trial results were announced October 12, and Canaccord raised its price target October 13; neither was directly linked to the decline.